Welcome to our dedicated page for Ultragenyx Pharm SEC filings (Ticker: RARE), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) SEC filings page provides access to the company’s official disclosures filed with the U.S. Securities and Exchange Commission. These documents include current reports on Form 8-K, quarterly and annual reports, and other filings that describe material agreements, financial results, and key developments in Ultragenyx’s rare disease business.
Form 8-K filings for Ultragenyx often cover topics such as royalty purchase agreements, clinical and regulatory milestones, and financial updates. For example, the company has reported a Royalty Purchase Agreement with an OMERS investment vehicle involving a portion of future Crysvita royalty payments in the United States and Canada, including details on purchase price, royalty percentages, and caps based on multiples of the purchase price. Other 8-Ks summarize press releases announcing quarterly financial results, revenue by product, operating expenses, and net loss.
Ultragenyx also uses Form 8-K to report clinical and regulatory events, including initiation and progress of rolling Biologics License Application submissions for DTX401 in glycogen storage disease type Ia, longer-term Phase 3 data for DTX401, Breakthrough Therapy Designation for GTX-102 in Angelman syndrome, enrollment status of the Phase 3 Aspire study, and FDA communications such as a Complete Response Letter for UX111 in Sanfilippo syndrome type A. These filings outline requested chemistry, manufacturing, and controls information and the company’s plans to address regulatory feedback.
Through Stock Titan, users can review Ultragenyx’s SEC filings and benefit from AI-powered summaries that explain the significance of complex documents, including 10-K and 10-Q reports when available, as well as Form 4 insider transaction reports. Real-time updates from EDGAR combined with AI-generated insights help readers understand how material agreements, clinical data, and regulatory interactions influence Ultragenyx’s operations and capital structure in the rare and ultra-rare genetic disease space.
Form 144 notice for proposed sales of Common Stock by an affiliate. The filing lists awarded restricted stock and performance shares with grant/vesting dates and quantities: 1,743, 1,343, 939, and 658 shares tied to dates between 10/09/2024 and 03/01/2026. The filing also records multiple reported sales by Howard Horn during the prior three months, including transactions on 02/02/2026, 03/02/2026, 03/03/2026, and 04/01/2026 with per‑trade share counts of 3,061, 5,290, 3,119, 1,635, and 4,683.
Ultragenyx Pharmaceutical Inc reports a passive institutional holding disclosure. Vanguard Portfolio Management reported beneficial ownership of 5,410,208 shares of Common Stock, representing 5.50% of the class as of 03/31/2026. The filing lists 24,216 shares of sole voting power and sole dispositive power over 5,410,208 shares. The filing is signed by Vanguard's Head of Global Fund Administration on 04/29/2026.
Ultragenyx Pharmaceutical Inc. reported that SVP and Chief Accounting Officer Theodore Alan Huizenga received an equity compensation grant. He was awarded 20,241 shares of common stock in the form of restricted stock units, increasing his direct holdings to 68,911 shares. These RSUs vest in four equal annual installments on each anniversary of the grant date, becoming fully vested after four years.
He also received a stock option for 7,348 shares of common stock with an exercise price of $24.61 per share, expiring on April 22, 2036. One quarter of the option vests on the first anniversary of the grant date, with the remainder vesting in equal monthly installments thereafter.
Ultragenyx Pharmaceutical Inc. President & CEO Emil D. Kakkis reported new equity compensation awards and updated indirect holdings. He received 76,745 Restricted Stock Units (RSUs) under the company’s 2023 Incentive Plan, which vest in four equal annual installments from the grant date.
He was also granted a stock option for 132,693 shares of common stock at an exercise price of $24.52 per share, vesting 25% on the first anniversary of the grant and the remainder monthly thereafter until 2036-04-16. Following these awards, he directly holds 735,739 shares of common stock.
The filing also reflects updated indirect ownership, including 1,758,985 shares held through the Emil Kakkis and Jenny Soriano Living Trust and an aggregate 400,000 shares contributed to two grantor retained annuity trusts (GRATs). These changes reflect compensation grants and estate-planning transfers rather than open-market trades.
Ultragenyx Pharmaceutical Inc. reported that officer Dennis Karl Huang received equity awards consisting of common stock and stock options. He was granted 23,116 shares of common stock as Restricted Stock Units (RSUs), bringing his direct common stock holdings to 147,845 shares after the award.
The RSUs were granted under the company’s 2023 Incentive Plan and vest in four equal annual installments on each anniversary of the grant date. Huang was also granted 79,936 stock options with an exercise price of $24.52 per share, expiring on April 16, 2036, which vest over four years with 1/4 vesting after one year and the remainder vesting monthly.
Ultragenyx Pharmaceutical Inc. executive John Richard Pinion received new equity awards in the form of restricted stock units and stock options. He was granted 23,116 shares of common stock as RSUs under the company’s 2023 Incentive Plan, bringing his direct common stock holdings to 133,142 shares after the award. These RSUs vest in four equal annual installments on each anniversary of the grant date.
He also received a stock option covering 79,936 shares of common stock at an exercise price of $24.52 per share, expiring on April 16, 2036. One quarter of the option vests on the first anniversary of the grant date, with the remainder vesting in equal monthly installments over the following three years.
Ultragenyx Pharmaceutical Inc. reported that EVP and Chief Legal Officer Karah Herdman Parschauer received an equity compensation package consisting of restricted stock units and stock options. She was granted 28,895 RSUs under the company’s 2023 Incentive Plan, vesting 25% on each anniversary of the grant date over four years. She was also granted a stock option for 49,960 shares of common stock at an exercise price of $24.52 per share, expiring on April 16, 2036, with 25% vesting after one year and the remainder vesting monthly thereafter. Following these grants, she directly holds 95,715 shares of common stock, including shares underlying previously reported RSUs that remain subject to vesting conditions.
Ultragenyx Pharmaceutical EVP & Chief Commercial Officer Erik Harris received new equity awards. He was granted 28,895 shares of common stock in the form of restricted stock units (RSUs) under the company’s 2023 Incentive Plan, bringing his direct common stock holdings to 118,410 shares.
He also received a stock option for 49,960 shares of common stock at an exercise price of $24.52 per share, expiring on April 16, 2036. The RSUs vest in four equal annual installments, while the option vests 25% on the first anniversary of the grant date and 1/48 monthly thereafter.
Ultragenyx Pharmaceutical EVP and Chief Medical Officer Eric Crombez received new equity awards as part of his compensation. He was granted 34,674 shares of Common Stock in the form of Restricted Stock Units (RSUs) under the company’s 2023 Incentive Plan.
The RSUs vest over four years, with one-quarter of the underlying shares vesting on each anniversary of the grant date. Crombez also received a stock option for 59,952 shares of Common Stock at an exercise price of $24.52 per share, expiring on April 16, 2036.
The option vests with one-quarter of the shares on the first anniversary of the grant date and the remainder in equal monthly installments thereafter. Following these awards, Crombez directly holds 110,975 shares of Common Stock, including previously reported RSU-based holdings subject to vesting conditions.
Ultragenyx Pharmaceutical Inc. Chief Financial Officer Howard Horn received new equity awards. He was granted 34,674 shares of common stock in the form of restricted stock units under the company’s 2023 Incentive Plan, bringing his direct common stock holdings to 115,025 shares.
The RSUs vest over four years, with one-quarter of the shares vesting on each anniversary of the grant date until fully vested on the fourth anniversary. Horn was also granted stock options for 59,952 shares of common stock at an exercise price of $24.52 per share, expiring on April 16, 2036. These options vest as to one-quarter of the shares on the first anniversary of the grant date and then in equal monthly installments over the following three years.